View Older Stories View More Recent Stories

Apr 14, 2022 07:00AM U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19
Apr 7, 2022 05:55AM Regeneron (REGN) Announces Dupixent Approved in EU for Children Aged 6-11 with Severe Asthma with Type Inflammation
Apr 7, 2022 01:00AM Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
Apr 7, 2022 12:59AM Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Apr 5, 2022 04:05PM Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022
Apr 4, 2022 05:51AM Regeneron (REGN) and Sanofi (SNY) Announces FDA Acceptance of Dupixent for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Apr 4, 2022 01:00AM Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
Apr 4, 2022 12:59AM FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Mar 26, 2022 10:00AM Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Mar 26, 2022 09:59AM Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
Mar 23, 2022 10:55AM (REGN Alert) Long Term Holders of Regeneron Contact Johnson Fistel for Information Regarding Investigation
Mar 15, 2022 09:16PM Students Win $1.8 Million at Regeneron Science Talent Search 2022 for Exceptional Research on Neutron Star--Black Hole Systems, Narrowband Radar, and Ribosome Movement in Protein Translation
Feb 28, 2022 04:02PM Intellia Therapeutics (NTLA) and Regeneron (REGN) Report Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulte
Feb 28, 2022 04:02PM Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustaine
Feb 28, 2022 04:01PM Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sus
Feb 28, 2022 05:47AM Regeneron (REGN) Reports Phase 3 Data Showing Dupixent Significantly Reduced Itch and Hives in Patients With Chronic Spontaneous Urticaria
Feb 26, 2022 12:05PM Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
Feb 26, 2022 12:04PM Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis
Feb 26, 2022 12:00PM Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Feb 26, 2022 11:59AM Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria
Feb 18, 2022 05:31AM Regeneron (REGN) and Sanofi (SNY) Announce CUPID STUDY B of Dupixent (dupilumab) Did Not Show Statistical Significance
Feb 18, 2022 01:00AM Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Feb 18, 2022 12:59AM Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Feb 17, 2022 04:05PM Regeneron Announces Investor Conference Presentations
Feb 11, 2022 07:51AM Regeneron (REGN) Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration
Feb 11, 2022 07:50AM Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
Feb 10, 2022 04:40AM Regeneron (REGN) Announces FDA Accepts for Review Dupixent in Children with Moderate-to-Severe Atopic Dermatitis
Feb 10, 2022 01:00AM FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Feb 10, 2022 12:59AM FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
Feb 4, 2022 06:30AM Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Feb 1, 2022 04:29PM Regeneron (REGN) to Present Positive Dupixent Data Across Five Diseases with Underlying Type 2 Inflammation
Feb 1, 2022 04:29PM Positive Dupixent® (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual Meeting
Jan 31, 2022 05:34AM Regeneron (REGN) Announces CHMP Recommends Approval of Dupixent for Children Aged 6 to 11
Jan 31, 2022 01:00AM CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
Jan 31, 2022 12:59AM CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Jan 28, 2022 07:01AM Regeneron (REGN), Sanofi (SNY) voluntary withdraw sBLA for Libtayo as second-line treatment for patients with advanced cervical cancer
Jan 28, 2022 07:00AM Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer
Jan 20, 2022 12:00PM Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search
Jan 20, 2022 12:00PM Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search
Jan 19, 2022 07:02AM Regeneron (REGN) Announces FDA Accepts for Review Libtayo in Combination with Chemotherapy
Jan 19, 2022 07:00AM FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC
Jan 19, 2022 05:35AM Regeneron (REGN) Announces Phase 3 of Dupixent Met Primary and Secondary Endpoints
Jan 19, 2022 01:00AM Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Jan 19, 2022 12:59AM Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis
Jan 13, 2022 04:05PM Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on
Jan 7, 2022 07:01AM Regeneron (REGN), Ultragenyx (RARE) Collaborate to Commercialize Evkeeza (evinacumab) Outside the United States
Jan 7, 2022 07:00AM Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States
Dec 22, 2021 04:15PM Regeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference
Dec 13, 2021 05:15AM Regeneron (REGN) Reports New REGN5458 Phase 1 Data Showing 75% Response Rate at Highest Dose Levels
Dec 13, 2021 04:53AM Regeneron (REGN) and Sanofi (SNY) Present Positive Phase 3 Dupixent Data in Children
View More Recent Stories View Older Stories